Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 1
2003 4
2005 8
2006 9
2007 8
2008 8
2009 7
2010 13
2011 6
2012 3
2013 7
2014 11
2015 11
2016 15
2017 25
2018 15
2019 18
2020 19
2021 27
2022 29
2023 24
2024 17
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Correspondence.
Feltgen N, Ach T, Bartz-Schmidt U, Bechrakis N, Eter N, Hattenbach L, Heimann H, Hoerauf H, Lommatzsch A, Priglinger S, Stahl A, Walter P, Wolf A, Ziemssen F, Grisanti S. Feltgen N, et al. Retina. 2024 Dec 1;44(12):e81-e83. doi: 10.1097/IAE.0000000000004265. Retina. 2024. PMID: 39316834 No abstract available.
Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation.
Pfau K, Lengyel I, Ossewaarde-van Norel J, van Leeuwen R, Risseeuw S, Leftheriotis G, Scholl HPN, Feltgen N, Holz FG, Pfau M. Pfau K, et al. Among authors: feltgen n. Prog Retin Eye Res. 2024 Sep;102:101274. doi: 10.1016/j.preteyeres.2024.101274. Epub 2024 May 28. Prog Retin Eye Res. 2024. PMID: 38815804 Free PMC article. Review.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Reply.
Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO. Hoerauf H, et al. Among authors: feltgen n. Am J Ophthalmol. 2016 Sep;169:292-293. doi: 10.1016/j.ajo.2016.06.016. Epub 2016 Jul 9. Am J Ophthalmol. 2016. PMID: 27401725 No abstract available.
[Chronic eye pain].
Erlenwein J, Petzke F, Tavernini T, Heindl LM, Feltgen N. Erlenwein J, et al. Among authors: feltgen n. Ophthalmologie. 2023 Dec;120(12):1216-1225. doi: 10.1007/s00347-023-01957-8. Epub 2023 Nov 24. Ophthalmologie. 2023. PMID: 37999754 Review. German.
Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN.
Torra R, Lipska-Zietkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E, van Eerde AM, Feltgen N, Ferrari R, Gale DP, Gear S, Gross O, Haeberle S, Heidet L, Lennon R, Massella L, Pfau K, Pizarro MDPV, Topaloglu R, Wlodkowski T, Zealey H; ERKNet, ERA Genes&Kidney and ESPN Inherited renal disorders working group. Torra R, et al. Among authors: feltgen n. Nephrol Dial Transplant. 2025 May 30;40(6):1091-1106. doi: 10.1093/ndt/gfae265. Nephrol Dial Transplant. 2025. PMID: 39673454 Free PMC article.
[N-Acetylcysteine (NAC) for Retinitis pigmentosa].
Pfau K, Callizo J, Rossouw P, Gabrani C, Holz F, Charbel Issa P, Kellner U, Strauss R, Kühlewein L, Stingl K, Feltgen N, Pfau M. Pfau K, et al. Among authors: feltgen n. Klin Monbl Augenheilkd. 2025 Mar;242(3):199-204. doi: 10.1055/a-2525-4419. Epub 2025 Jan 26. Klin Monbl Augenheilkd. 2025. PMID: 39864434 Review. German.
272 results